{
    "info": {
        "nct_id": "NCT06192680",
        "official_title": "A Multicenter, Single-arm Study of Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer",
        "inclusion_criteria": "* Age: ≥18 years old.\n* Histopathologically and/or cytologically confirmed unresectable metastatic colorectal adenocarcinoma, and patients failed or are intolerant to first-line treatment with oxaliplatin ± VEGF/EGFR.\n* At least one measurable lesion (according to RECIST v1.1).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 ~ 1.\n* The expected survival time ≥3 months.\n* Subject has adequate biological parameters as demonstrated by the following: Absolute neutrophil count (ANC) ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hgb) ≥90 g/L.\n* Adequate hepatic function as evidenced by: Total bilirubin ≤1.5 × upper limit of normal (ULN), Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, ≤5 × ULN if liver metastases are present. Serum albumin ≥3 g/dL.\n* Adequate renal function as evidenced by serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance ≥60 mL/min. Proteinuria < 2+ (those with proteinuria ≥2+ at baseline had to demonstrate ≤1 g protein per 24 hours).\n* Coagulation function: International normalised ratio (INR) ≤1.5, activated partial thromboplastin time (APTT) ≤1.5 × ULN.\n* Left ventricular ejection fraction (LVEF) ≥50%.\n* Subjects agree to use contraception and are not pregnant or breastfeeding women.\n* Agree and be able to comply with the plan during the study period. Provide written informed consent before entering the study screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
        "exclusion_criteria": "* Any other malignancy within 5 years, with the exception of cured in-situ carcinoma or basal cell carcinoma etc.\n* Previous treatment with irinotecan/liposomal irinotecan.\n* Patients with the primary lesion located in the left colon and RAS/BRAF wild-type who did not use cetuximab on the first line.\n* Known as high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).\n* Massive pleural effusion or ascites requiring intervention.\n* Active, uncontrolled bacterial, viral, or fungal infections that require systemic treatment.\n* Active HIV infection.\n* Combined with uncontrollable systemic diseases within 6 months before the first administration.\n* Presence of severe gastrointestinal disease.\n* History of major surgery (such as laparotomy, thoracotomy or intestinal resection) within 28 days before the first administration, or plan to undergo major surgery during the study period.\n* Presence of interstitial pneumonia or pulmonary fibrosis.\n* History of allergy or hypersensitivity to drug or any of their excipients.\n* History of pulmonary hemorrhage/hemoptysis ≥Grade 2 (defined as bright red blood of at least 2.5mL) within one month before the first administration.\n* Presence of arterial embolism, severe bleeding (excluding bleeding caused by surgery) or tendency for existing embolism or severe bleeding within 6 months before the first administration.\n* Combined symptomatic brain metastasis, meningeal metastasis, spinal cord tumor invasion, and spinal cord compression syndrome.\n* Use of strong inhibitors or inducers of CYP3A4, CYP2C8 and UGT1A1 within 14 days before the first administration.\n* Use other study drug within 1 month before the first administration.\n* Patients who are not suitable to participate in this trial for any reason judged by the investigator.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Age: ≥18 years old.",
            "criterions": [
                {
                    "exact_snippets": "Age: ≥18 years old.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histopathologically and/or cytologically confirmed unresectable metastatic colorectal adenocarcinoma, and patients failed or are intolerant to first-line treatment with oxaliplatin ± VEGF/EGFR.",
            "criterions": [
                {
                    "exact_snippets": "Histopathologically and/or cytologically confirmed",
                    "criterion": "confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histopathological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable metastatic colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "unresectable metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients failed or are intolerant to first-line treatment with oxaliplatin ± VEGF/EGFR",
                    "criterion": "first-line treatment with oxaliplatin ± VEGF/EGFR",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "failed",
                                "intolerant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one measurable lesion (according to RECIST v1.1).",
            "criterions": [
                {
                    "exact_snippets": "At least one measurable lesion (according to RECIST v1.1)",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 ~ 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 ~ 1.",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The expected survival time ≥3 months.",
            "criterions": [
                {
                    "exact_snippets": "expected survival time ≥3 months",
                    "criterion": "expected survival time",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subject has adequate biological parameters as demonstrated by the following: Absolute neutrophil count (ANC) ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hgb) ≥90 g/L.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥1.5×10^9/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelet count ≥100×10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin (Hgb) ≥90 g/L",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hepatic function as evidenced by: Total bilirubin ≤1.5 × upper limit of normal (ULN), Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, ≤5 × ULN if liver metastases are present. Serum albumin ≥3 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 × upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "× ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN, ≤5 × ULN if liver metastases are present",
                    "criterion": "AST and ALT",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": [
                                ":{"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum albumin ≥3 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal function as evidenced by serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance ≥60 mL/min. Proteinuria < 2+ (those with proteinuria ≥2+ at baseline had to demonstrate ≤1 g protein per 24 hours).",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal function as evidenced by serum creatinine (Cr) ≤1.5 × ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "× ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate renal function ... creatinine clearance ≥60 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Proteinuria < 2+",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "those with proteinuria ≥2+ at baseline had to demonstrate ≤1 g protein per 24 hours",
                    "criterion": "proteinuria",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g protein per 24 hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Coagulation function: International normalised ratio (INR) ≤1.5, activated partial thromboplastin time (APTT) ≤1.5 × ULN.",
            "criterions": [
                {
                    "exact_snippets": "Coagulation function: International normalised ratio (INR) ≤1.5",
                    "criterion": "International normalised ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Coagulation function: ... activated partial thromboplastin time (APTT) ≤1.5 × ULN",
                    "criterion": "activated partial thromboplastin time (APTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "× ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) ≥50%.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects agree to use contraception and are not pregnant or breastfeeding women.",
            "criterions": [
                {
                    "exact_snippets": "Subjects agree to use contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not pregnant",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not ... breastfeeding women",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree and be able to comply with the plan during the study period. Provide written informed consent before entering the study screening.",
            "criterions": [
                {
                    "exact_snippets": "Agree and be able to comply with the plan during the study period.",
                    "criterion": "compliance with study plan",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Provide written informed consent before entering the study screening.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 80 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 80 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 80,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any other malignancy within 5 years, with the exception of cured in-situ carcinoma or basal cell carcinoma etc.",
            "criterions": [
                {
                    "exact_snippets": "Any other malignancy within 5 years",
                    "criterion": "other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cured in-situ carcinoma",
                    "criterion": "cured in-situ carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "basal cell carcinoma",
                    "criterion": "basal cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with irinotecan/liposomal irinotecan.",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with irinotecan",
                    "criterion": "previous treatment with irinotecan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with ... liposomal irinotecan",
                    "criterion": "previous treatment with liposomal irinotecan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the primary lesion located in the left colon and RAS/BRAF wild-type who did not use cetuximab on the first line.",
            "criterions": [
                {
                    "exact_snippets": "primary lesion located in the left colon",
                    "criterion": "primary lesion location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "left colon"
                        }
                    ]
                },
                {
                    "exact_snippets": "RAS/BRAF wild-type",
                    "criterion": "RAS/BRAF status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "did not use cetuximab on the first line",
                    "criterion": "cetuximab usage",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known as high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).",
            "criterions": [
                {
                    "exact_snippets": "high microsatellite instability (MSI-H)",
                    "criterion": "microsatellite instability",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "mismatch repair deficiency (dMMR)",
                    "criterion": "mismatch repair",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "deficiency"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Massive pleural effusion or ascites requiring intervention.",
            "criterions": [
                {
                    "exact_snippets": "Massive pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "massive"
                        },
                        {
                            "requirement_type": "intervention",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites requiring intervention",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "intervention",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, uncontrolled bacterial, viral, or fungal infections that require systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active, uncontrolled bacterial, viral, or fungal infections",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "require systemic treatment",
                    "criterion": "systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active HIV infection.",
            "criterions": [
                {
                    "exact_snippets": "Active HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Combined with uncontrollable systemic diseases within 6 months before the first administration.",
            "criterions": [
                {
                    "exact_snippets": "uncontrollable systemic diseases",
                    "criterion": "systemic diseases",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrollable"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6 months before the first administration",
                    "criterion": "time since diagnosis or control",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of severe gastrointestinal disease.",
            "criterions": [
                {
                    "exact_snippets": "Presence of severe gastrointestinal disease",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of major surgery (such as laparotomy, thoracotomy or intestinal resection) within 28 days before the first administration, or plan to undergo major surgery during the study period.",
            "criterions": [
                {
                    "exact_snippets": "History of major surgery (such as laparotomy, thoracotomy or intestinal resection) within 28 days before the first administration",
                    "criterion": "history of major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to undergo major surgery during the study period",
                    "criterion": "plan to undergo major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "during the study period"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of interstitial pneumonia or pulmonary fibrosis.",
            "criterions": [
                {
                    "exact_snippets": "Presence of interstitial pneumonia",
                    "criterion": "interstitial pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergy or hypersensitivity to drug or any of their excipients.",
            "criterions": [
                {
                    "exact_snippets": "History of allergy or hypersensitivity to drug",
                    "criterion": "allergy or hypersensitivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy or hypersensitivity to ... any of their excipients",
                    "criterion": "allergy or hypersensitivity to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of pulmonary hemorrhage/hemoptysis ≥Grade 2 (defined as bright red blood of at least 2.5mL) within one month before the first administration.",
            "criterions": [
                {
                    "exact_snippets": "History of pulmonary hemorrhage/hemoptysis",
                    "criterion": "pulmonary hemorrhage/hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "≥Grade 2 (defined as bright red blood of at least 2.5mL)",
                    "criterion": "pulmonary hemorrhage/hemoptysis severity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within one month before the first administration",
                    "criterion": "time since last pulmonary hemorrhage/hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "time since last occurrence",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of arterial embolism, severe bleeding (excluding bleeding caused by surgery) or tendency for existing embolism or severe bleeding within 6 months before the first administration.",
            "criterions": [
                {
                    "exact_snippets": "Presence of arterial embolism",
                    "criterion": "arterial embolism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe bleeding (excluding bleeding caused by surgery)",
                    "criterion": "severe bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tendency for existing embolism",
                    "criterion": "tendency for existing embolism",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tendency for ... severe bleeding",
                    "criterion": "tendency for severe bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 6 months before the first administration",
                    "criterion": "time since last event",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Combined symptomatic brain metastasis, meningeal metastasis, spinal cord tumor invasion, and spinal cord compression syndrome.",
            "criterions": [
                {
                    "exact_snippets": "symptomatic brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meningeal metastasis",
                    "criterion": "meningeal metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord tumor invasion",
                    "criterion": "spinal cord tumor invasion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord compression syndrome",
                    "criterion": "spinal cord compression syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of strong inhibitors or inducers of CYP3A4, CYP2C8 and UGT1A1 within 14 days before the first administration.",
            "criterions": [
                {
                    "exact_snippets": "Use of strong inhibitors or inducers of CYP3A4",
                    "criterion": "use of strong inhibitors or inducers of CYP3A4",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 14 days before the first administration"
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of strong inhibitors or inducers of ... CYP2C8",
                    "criterion": "use of strong inhibitors or inducers of CYP2C8",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 14 days before the first administration"
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of strong inhibitors or inducers of ... UGT1A1",
                    "criterion": "use of strong inhibitors or inducers of UGT1A1",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 14 days before the first administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use other study drug within 1 month before the first administration.",
            "criterions": [
                {
                    "exact_snippets": "Use other study drug within 1 month before the first administration.",
                    "criterion": "use of other study drug",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are not suitable to participate in this trial for any reason judged by the investigator.",
            "criterions": [
                {
                    "exact_snippets": "not suitable to participate in this trial for any reason judged by the investigator",
                    "criterion": "suitability for trial participation",
                    "requirements": [
                        {
                            "requirement_type": "judgment",
                            "expected_value": "investigator's discretion"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}